To evaluate the effects of combining the assessment of circulating high-sensitivity C-reactive protein ( hs-CRP ) with that of Epstein-Barr virus DNA ( EBV DNA ) in the pretherapy prognostication of nasopharyngeal carcinoma ( NPC ) .